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ABSTRACT 
 
Objectives In order to increase our understanding of the aetiology and pathogenesis 
in rheumatoid arthritis (RA), we have investigated genetic and environmental risk 
factors for RA subsets, defined by the presence or absence of different anti-
citrullinated protein/peptide antibodies (ACPAs), targeting citrullinated peptides from 
α-enolase, vimentin, fibrinogen and collagen type II.  
 
Methods RA cases (n=1985) and matched controls (n=2252) from the EIRA case-
control cohort were used in this study. Serum samples were assayed by ELISA for 
presence of anti-CCP antibodies and four different ACPA fine-specificities. Cross-
reactivity between ACPAs was examined by peptide-absorption experiments. 
Genotyping was performed for HLA-DRB1 ‘shared epitope’ (SE) alleles and the 
PTPN22 gene, while information regarding smoking was obtained by questionnaire.  
Association of genetic and environmental risk factors with different subsets of RA 
was calculated by means of logistic regression analysis. 
 
Results Limited cross-reactivity was observed between different ACPA fine-
specificities. In total, 17 RA subsets could be identified based on their different 
ACPA fine-specificity profiles. Large differences in association with genetic and 
environmental determinants were observed between subsets. Strongest association of 
HLA-DRB1 SE, PTPN22 and smoking was identified for the RA subset which was 
defined by the presence of antibodies to citrullinated α-enolase and vimentin. 
 
Conclusion Our study provides the most comprehensive picture to this date, of how 
HLA-DRB1 SE, PTPN22 and smoking associate with the presence of specific ACPA-
reactivities, rather than anti-CCP levels. The new data will form a basis for molecular 
studies aimed at understanding disease development in serologically distinct subsets 
of RA. 
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INTRODUCTION 
 
Rheumatoid arthritis (RA) has for many years been considered a prototype for 
immune-mediated diseases, due to the strong genetic association with certain MHC 
class II alleles, i.e. HLA-DRB1 shared epitope (SE),[1-3]. More recently, the MHC 
class II association in RA was shown to be confined to the subset of patients which is 
characterised by the presence of antibodies to synthetic cyclic citrullinated peptides 
(CCP),[4, 5]. The concomitant recognition, that the best-known environmental risk 
factor for RA, namely smoking, constitutes a risk only for the development of CCP 
positive disease, together with the finding that smoking induces the exposure of 
citrullinated proteins in the lungs,[4, 6, 7], suggest an aetiology for RA where HLA-
DRB1 SE-restricted immune reactions to citrullinated epitopes trigger and drive 
disease pathogenesis,[8]. Subsequently, it has been demonstrated that the CCP assays, 
such as the most frequently used CCP2 ELISA, is able to capture anti-citrullinated 
protein/peptide antibodies (ACPAs) with a rather broad spectrum of fine-specificities, 
including naturally occurring citrullinated autoantigens,[9, 10]. 
 
In order to increase our understanding of RA aetiology and pathogenesis, it has thus 
become an important task to define which ACPA fine-specificities associate with the 
different HLA-DRB1 SE alleles. Such studies have been performed for some ACPA 
fine-specificities,[11-15], and differences within the CCP positive population have 
been described. However, no comprehensive picture has emerged so far, partly 
because only single target antigens have been studied, and partly due to small study 
populations, and lack of information on appropriate controls. Hence, in the present 
study we have used the large and well-characterised EIRA (Epidemiological 
Investigation of Rheumatoid Arthritis) case-control cohort,[16], to investigate HLA-
DRB1 SE, in combination with PTPN22 polymorphism - the second most important 
genetic risk factor for CCP positive RA,[17] - and cigarette smoking, in relation to the 
presence of antibodies targeting four well-defined citrullinated autoantigens 
(citrullinated α-enolase, -vimentin, -fibrinogen and -collagen type II).  
 
METHODS 
 
Subjects 
The Epidemiological Investigation of RA (EIRA) is an on-going Swedish population-
based case-control study, described in detail elsewhere,[16]. In the present study, we 
analysed 1985 incident cases of RA, included in the EIRA study between May 1996 - 
May 2006, and 2252 controls, randomly selected from the national population 
register, to match RA cases in terms of age, gender and residential area. Cases were 
diagnosed with RA according to the 1987 ACR criteria,[18]. Cases and controls 
donated blood at the time of inclusion and completed a self-administered 
questionnaire, relating to life style and environmental exposures. 
 
ELISAs 
Anti-CCP antibody status was determined in sera from 1985 EIRA cases and 1210 
controls, using the CCP2 assay (Immunoscan CCPlus, Euro-Diagnostica), according 
the manufacturer’s instructions. Cut-off for positivity was 25AU/ml. Antibody 
responses to citrullinated peptides from α-enolase (CEP-1), vimentin (Cit-vim), 
fibrinogen (Cit-fib) and collagen type II (Cit-C1), or the arginine-containing 
equivalents, were assayed in sera from 1985 EIRA cases and 150 randomly selected 
EIRA controls, using in-house ELISAs, as previously described,[11, 19]. Cut-off for 
positivity was 10AU/ml for all ACPA fine-specificities. See data supplement online, 
for a detailed description of the ELISA method.  
 
Cross-reactivity assay 
Ten serum samples with high anti-CCP levels (>800 AU/ml), that also displayed 
reactivity to CEP-1 (n=10), Cit-vim (n= 8), Cit-fib (n=9) and Cit-C1 (n=8), were 
selected from EIRA for cross-reactivity experiments. Each serum (diluted 1:100) was 
incubated with each of the four peptides (CEP-1, Cit-vim, Cit-fib or Cit-C1) at 
10µg/ml, or in the presence of buffer alone. Pre-absorption was performed in liquid-
phase during constant agitation for 2h, at room temperature. Following centrifugation 
(15 minutes, 1000g), supernatants were transferred to the four peptide ELISA plates, 
and assayed as described above. Inhibition was determined based on the differences in 
AU/ml values between the absorbing peptide and buffer alone. 
 
Peptides 
Freeze-dried synthetic peptides (>95% purity), corresponding to sequences from 
human α-enolase (amino acid 5-21), vimentin (amino acid 60-75) and fibrinogen 
(amino acid 36-52), in its ‘native’ form or with arginine-to-citrulline substitutions 
(Innovagen, Sweden), were dissolved at 10mg/ml (Milli-Q water, 10% DMSO) and 
stored at -20°C before used. The homotrimeric triple-helical collagen type II peptides, 
C1 and Cit-C1, were synthesized as previously described,[20, 21]. See supplementary 
Table 1, for a detailed description of the peptide sequences.  
 
Genotyping 
HLA-DRB1 subtyping was performed on DNA samples from 1961 RA cases and 
1278 controls, by sequence-specific primer polymerase chain reaction, as previously 
described,[11]. DRB1*01 (except DRB1*0103), DRB1*04 and DRB1*10 were 
classified as ‘shared epitope’ (SE) alleles of HLA-DRB1. The protein tyrosine 
phosphatase gene (PTPN22 rs2476601) was genotyped on 1943 RA cases and 1284 
controls, as previously described,[17].  
 
Cigarette smoking 
Information regarding cigarette smoking, antedating symptoms of arthritis in 1727 
RA cases, and the corresponding time points among 1913 controls, were obtained by 
questionnaire. Individuals were categorized as ever smokers (current/past) or never 
smokers,[16].  
 
Statistical analyses 
To determine the association of HLA-DRB1 SE (alone or in combination with 
PTPN22 and/or smoking) with different subsets of RA, odds ratios (OR), together 
with 95% confidence intervals (CI), were calculated using unconditional logistic 
regression analyses, with cases and controls that were negative for the risk factors as 
referent category. All analyses were performed with adjustment for design variables 
(age, residential area and gender).  
 
Interaction, as defined by departure from additivity of effects,[22], was evaluated 
between HLA-DRB1 SE and smoking, and between HLA-DRB1 SE and PTPN22. The 
attributable proportion due to interaction (AP) was calculated together with 95% CI, 
as previously described,[11, 23]. The AP between two interacting factors reflects the 
joint effect beyond the sum of the independent effects. All analyses were performed 
using the Statistical Analysis System (SAS), version 9.1. 
 
Differences in ACPA levels, between different RA subsets, or between absorbing 
peptides and buffer in the cross-reactivity experiment, were examined using Mann-
Whitney U test for independent groups. 
 
RESULTS 
 
Identification of different RA subsets, based on ACPA fine-specificity profiles  
Sixty three per cent of RA cases in EIRA were anti-CCP antibody positive; 35% anti-
CEP-1 positive; 37% anti-Cit-vim positive; 28% anti-Cit-fib positive; and 37% were 
positive for anti-Cit-C1 antibodies. Low-level antibody responses to the arginine-
containing control peptides from α-enolase, vimentin and fibrinogen were detected in 
less than 2.4% of patients, while reactivity to the arginine-containing C1 peptide,[20, 
21, 24] of collagen type II was detected in 9% (data not shown). The presence of 
different ACPA fine-specificities overlapped to a large extent, and by analysing the 
different patterns, 17 serologically distinct subsets could be identified (figure 1a). A 
great majority of patients, which were positive for the specific ACPAs, were confined 
to the CCP positive population, although 18% of the CCP negative patients were 
positive for at least one ACPA fine-specificity (figure 1b). Conversely, 8.7% of all 
patients were CCP positive but negative for the four ACPA fine-specificities. 
 
In the CCP negative population, ACPA positive patients typically showed reactivity 
to only one citrullinated antigen, where anti-Cit-C1 antibodies were dominant 
(9.45%). In the CCP positive subset on the other hand, presence of two (16.6%), three 
(13.4%) or four (11%) ACPA fine-specificities were common. ACPA fine-specificity 
levels were generally lower in the CCP negative, compared to the CCP positive 
population (data not shown). Moreover, there was a strong correlation between 
number of ACPAs present and anti-CCP antibody levels, with a significant 
(p<0.0001) increase of anti-CCP antibody levels for every additional ACPA fine-
specificity (supplementary figure 1).  
 
ACPAs show limited cross-reactivity 
In order to analyse the extent of cross-reactivity between antibodies reactive with the 
different citrullinated peptides, serum samples from 10 CCP positive RA patients, 
with antibodies to CEP-1 (n=10), Cit-vim (n=8), Cit-fib (n=9) and Cit-C1 (n=8), were 
pre-absorbed against each of the four peptides, before re-tested for ACPA-reactivities. 
All four ACPAs were efficiently absorbed by pre-incubation with its homologous 
peptide, while only limited cross-reactivity was observed between specificities. Anti-
CEP-1 IgG showed low-degree cross-reactivity with Cit-fib in some sera (p = 0.043), 
but no cross-reactivity with Cit-vim or Cit-C1 (figure 2a). Anti-Cit-vim IgG showed 
cross-reactivity with Cit-fib in two serum samples (figure 2b). Anti-Cit-fib IgG 
showed some degree of cross-reactivity with CEP-1 in some sera (p = 0.050) (figure 
2c), and anti-Cit-C1 antibodies showed cross-reactivity mainly with Cit-fib, in 
approximately half of the serum samples (p < 0.001) (figure 2d). 
 
HLA-DRB1 SE, in combination with PTPN22 and smoking, associate mainly 
with CEP-1 and Cit-vim positive RA 
To investigate associations of genetic and environmental risk factors with different 
subsets of RA, we first defined RA subsets by the presence or absence of antibodies 
to single citrullinated peptides, i.e. without taking into account which additional 
ACPA fine-specificities may also be present in the subset. As seen in figure 3a, being 
positive for HLA-DRB1 SE, PTPN22 and smoking associated mainly with CEP-1 
positive RA (OR=39.1), compared to CEP-1 negative/CCP positive RA (OR=7.9). A 
similar pattern was observed for antibodies to Cit-vim, where the association of HLA-
DRB1 SE, in combination with PTPN22 and smoking, was stronger with Cit-vim 
positive (OR=25.6) compared to Cit-vim negative/CCP positive disease (OR=8.9) 
(figure 3b). Subsets defined by antibodies to Cit-fib or Cit-C1, on the other hand, did 
not demonstrate such specific associations, beyond the effect of CCP (OR=15.6 
versus 12.9 for Cit-fib, and 10.0 versus 13.8 for Cit-C1) (figure 3c and d). 
 
Impact of HLA-DRB1 SE on disease risk in different subsets of RA 
The results described in the previous paragraph may be influenced by the co-existence 
of multiple ACPA fine-specificities. Hence, we next investigated the four RA subsets 
which were defined by the sole presence of one ACPA-fine-specificity, i.e. the 
subsets that were ‘single positive’ for anti-CEP-1, anti-Cit-vim, anti-Cit-fib or anti-
Cit-C1 antibodies. In this analysis we focused on HLA-DRB1 SE, the risk factor with 
strongest impact. We found a relatively strong association of HLA-DRB1 SE with 
CEP-1 positive (OR=5.1), as well as with Cit-vim positive disease (OR=6.0), but not 
with Cit-fib positive disease (OR=1.4), and the association with Cit-C1 positive RA 
was weak (OR=1.6) (table 1). A significant association of HLA-DRB1 SE (OR=2.5; 
95% CI=1.8-3.6) could also be observed with the subset which was positive for CCP 
but negative for all four ACPA fine-specificities (data not shown). 
 
Table 1. Odds ratios for disease risk in different subsets of RA - in carriers of HLA-DRB1 SE, 
compared to non-carriers 
HLA-DRB1 SE ACPAs CEP-1/Cit-vim/Cit-fib/Cit-C1 any none OR* 95% CI 
control group na 643 635 1.0  ref. 
+/-/-/- 59 12 5.1  2.7-9.5 
-/+/-/- 108 18 6.0  3.6-10.0 
-/-/+/- 28 21 1.4  0.75-2.5 
-/-/-/+ 91 57 1.6  1.11-2.3 
+/+/-/- 97 2 49.6  12.1-202.5 
+/-/+/- 21 7 3.2  1.3-7.6 
+/-/-/+ 43 3 15.0  4.6-49.0 
-/+/+/- 18 8 2.3  1.0-5.4 
-/+/-/+ 69 10 6.9  3.5-13.6 
case groups 
-/-/+/+ 36 14 2.5  1.3-4.7 
* adjusted for age, gender, and residence area 
We then studied the effect of being positive for different combinations of two ACPA 
fine-specificities, as the impact of HLA-DRB1 SE may differ between subsets defined 
by specific combinations of non-cross reactive ACPAs. Strongest influence of HLA-
DRB1 SE was identified for CEP-1/Cit-vim double positive disease (OR=49.6), while 
the odds ratio for the association with Cit-fib/Cit-C1 double positive RA was merely 
2.5. Interestingly, anti-CCP antibody levels were higher in the Cit-fib/Cit-C1 double 
positive subset than in the CEP-1/Cit-vim double positive subset, implicating that 
HLA-DRB1 SE mainly influence the fine-specificity of the ACPA response, rather 
than anti-CCP levels (supplementary figure 2). 
 
Impact of smoking, in combination with HLA-DRB1 SE, on disease risk in 
different subsets of RA  
Since the data presented above do not support an association of HLH-DRB1 SE with 
the presence of anti-Cit-fib antibodies, we restricted the next analysis to RA 
subgroups defined by the presence or absence of antibodies to CEP-1, Cit-vim and 
Cit-C1. Here, we had enough power to investigate the combined effect of HLA-DRB1 
SE and smoking. As shown in table 2, smoking in the absence of HLA-DRB1 SE did 
not significantly associate with any RA subset, but strengthened the HLA-DRB1 SE 
association when present. This effect was most pronounced for ‘double positive’ and 
‘triple positive’ subsets, compared to ‘single positive’ subsets, but only when anti-
CEP-1 antibodies were present. Adding Cit-vim reactivity to the CEP-1 single 
positive subset, increased the odds ratio for the combined HLA-DRB1 SE and 
smoking association from 12.5 to 18.4. A similar effect was seen when adding Cit-C1 
reactivity to the CEP-1 single positive subset (from OR=12.5 to 17.2). However, in 
the absence of anti-CEP-1 antibodies, addition of Cit-C1 reactivity to the Cit-vim 
single positive subgroup did not increase the odds ratios further (7.3 versus 5.6). 
Highest odds ratio (23.3), for the combined HLA-DRB1 SE and smoking association, 
was observed for the ‘triple positive’ subset (CEP-1+/Cit-vim+/Cit-C1+). 
  
 
Table 2. Odds ratios for disease risk in different subsets of RA - in subjects exposed to different 
combinations of HLA-DRB1 SE and smoking, compared to non-exposed subjects 
CEP-1/Cit-vim/Cit-C1 HLA-DBR1 SE Smoking Cases/controls OR* 95% CI 
-/-/- - - 115/228 1 Ref. 
-/-/- + - 176/244 1.4 1.1-1.9 
-/-/- - + 173/316 1.1 0.8-1.5 
-/-/- + + 233/315 1.6 1.2-2.1 
+/-/- - - 3/228 1 Ref. 
+/-/- + - 25/244 8 2.4-27.0 
+/-/- - + 13/316 3.3 0.9-11.9 
+/-/- + + 46/315 12.5 3.8-40.9 
-/+/- - - 7/228 1 Ref. 
-/+/- + - 42/244 5.8 2.5-13.3 
-/+/- - + 15/316 1.7 0.7-4.3 
-/+/- + + 64/315 7.3 3.2-16.4 
-/-/+ - - 35/228 1 Ref. 
-/-/+ + - 41/244 1.1 0.7-1.8 
-/-/+ - + 31/316 0.6 0.4-1.1 
-/-/+ + + 68/315 1.4 0.9-2.3 
+/+/- - - 5/228 1 Ref. 
+/+/- + - 29/244 5.5 2.1-14.5 
+/+/- - + 7/316 1 0.3-3.3 
+/+/- + + 118/315 18.4 7.3-46.1 
+/-/+ - - 3/228 1 Ref. 
+/-/+ + - 25/244 7.7 2.3-26.1 
+/-/+ - + 11/316 2.7 0.7-10.0 
+/-/+ + + 65/315 17.2 5.3-55.8 
-/+/+ - - 7/228 1 Ref. 
-/+/+ + - 27/244 3.5 1.5-8.4 
-/+/+ - + 10/316 1 0.4-2.8 
-/+/+ + + 52/315 5.6 2.5-12.7 
+/+/+ - - 6/228 1 Ref. 
+/+/+ + - 54/244 8.5 3.6-20.1 
+/+/+ - + 14/316 1.6 0.6-4.3 
+/+/+ + + 189/315 23.3 10.1-53.7 
*:Adjusted for age, gender and residential area 
Impact of PTPN22, in combination with HLA-DRB1 SE, on disease risk in 
different subsets of RA  
We then investigated the combined effect of HLA-DRB1 SE and PTPN22 in subsets 
defined by anti-CEP-1, anti-Cit-vim and anti-Cit-C1 antibody status. As seen with 
smoking, PTPN22 also mainly had an effect in the presence of HLA-DRB1 SE, and 
also this association was most pronounce for ‘double positive’ and ‘triple positive’ 
subsets, encompassing anti-CEP-1 antibodies. Addition of Cit-vim reactivity to the 
CEP-1 single positive subset increased the odds ratio for the combined HLA-DRB1 
SE and PTPN22 association from 8.7 to 29.2, while addition of Cit-C1 to the CEP-1 
single positive subset changed the odds ratio from 8.7 to 17.1. However, similar odds 
ratios were observed for the Cit-vim single positive and the Cit-vim/Cit-C1 double 
positive subsets (8.4 versus 8.7). Strongest association (OR=34.8), of the HLA-DRB1 
SE and PTPN22 combination, was seen with the ‘triple positive’ subset (CEP-1+/Cit-
vim+/Cit-C1+) (supplementary table 2). 
 
The combined effect of HLA-DRB1 SE, PTPN22 and smoking on disease risk in 
subsets of RA defined by anti-CEP-1 and anti-Cit-vim antibody status 
In the final analysis we investigated the combined effect of all three risk factors 
(HLA-DRB1 SE, PTPN22 and smoking), and calculated gene-environment and gene-
gene interactions. Here we focused on what appears to be the two most important 
ACPA fine-specificities in this context, and defined RA subgroups based on CEP-1 
and Cit-vim reactivity alone (table 3). Presence of HLA-DRB1 SE alleles, PTPN22 
polymorphism and cigarette smoking conferred a rather modest risk for the 
development of CEP-1 negative/Cit-vim negative disease (OR=2.4), while the risk 
was high for CEP-1 positive/Cit-vim negative RA (OR=24.4) and for CEP-1 
negative/Cit-vim positive RA (OR=11.5). However, highest risk was identified for the 
CEP-1/Cit-vim double positive subset (OR=50.1).  
 
 
Table 3. Odds ratios for disease risk in different subsets of RA - in subjects exposed to different 
combinations of HLA-DRB1 SE, smoking and PTPN22, compared to non-exposed subjects 
CEP-1/Cit-vim HLA-DRB1 SE Smoking PTPN22 Cases/controls OR* 95% CI 
-/- - - - 106/178 1 Ref. 
-/- - - + 41/49 1.4 0.9-2.3 
-/- + - - 168/200 1.4 1.0-1.9 
-/- + - + 47/43 2 1.2-3.2 
-/- - + - 140/233 1 0.8-1.4 
-/- - + + 61/81 1.4 0.9-2.1 
-/- + + - 223/252 1.6 1.1-2.1 
-/- + + + 76/61 2.4 1.5-3.6 
+/- - - - 4/178 1 Ref. 
+/- - - + 2/49 1.9 0.3-10.7 
+/- + - - 32/200 7 2.4-20.3 
+/- + - + 18/43 20.1 6.4-63.2 
+/- - + - 13/233 2.6 0.8-8.2 
+/- - + + 10/81 5.7 1.7-18.8 
+/- + + - 80/252 15.4 5.5-43.1 
+/- + + + 29/61 24.4 8.2-73.1 
-/+ - - - 10/178 1 Ref. 
-/+ - - + 4/49 1.7 0.5-5.7 
-/+ + - - 47/200 4.3 2.1-8.8 
-/+ + - + 22/43 9.9 4.3-22.8 
-/+ - + - 21/233 1.7 0.8-3.8 
-/+ - + + 4/81 1 0.3-3.3 
-/+ + + - 83/252 6.3 3.2-12.7 
-/+ + + + 33/61 11.5 5.3-25.3 
+/+ - - - 6/178 1 Ref. 
+/+ - - + 5/49 3.4 1.0-11.7 
+/+ + - - 43/200 6.4 2.7-15.6 
+/+ + - + 40/43 30.4 12.0-76.9 
+/+ - + - 14/233 1.8 0.7-4.8 
+/+ - + + 7/81 2.7 0.9-8.2 
+/+ + + - 212/252 26.6 11.5-61.7 
+/+ + + + 92/61 50.1 20.6-121.8 
*:Adjusted for age, gender and residential area 
 
Analyses of interaction, calculated as the attributable proportion due to interaction 
(AP),[22-23], demonstrated significant interactions between HLA-DRB1 SE and 
smoking in the CEP-1 positive/Cit-vim negative as well as in the CEP-1/Cit-vim 
double positive subsets, with AP values of 0.33 and 0.64, respectively. Interactions 
were also observed between HLA-DRB1 SE and PTPN22 in the CEP-1 positive/Cit-
vim negative (AP=0.44), the CEP-1 negative/Cit-vim positive (AP=0.56) and in the 
CEP-1/Cit-vim double positive subsets (AP=0.53) (supplementary table 3). 
DISCUSSION 
 
The present study provides novel data concerning the relationships between specific 
autoimmune reactions and genetic and environmental determinants for the risk of 
developing RA, with the overall conclusion that HLA-DRB1 SE genes, the PTPN22 
risk allele and cigarette smoking associate with the presence of specific ACPA-
reactivities, rather than total levels of anti-CCP antibodies. 
 
We have focused our analyses on antibody responses to well-defined citrullinated 
epitopes on α-enolase,[25, 26], vimentin,[13, 27], fibrinogen,[28, 29] and collagen 
type II,[21], representing physiological antigens present in the rheumatoid joint. A 
vast majority of patients that were positive for these ACPA fine-specificities were 
also positive in the CCP2 ELISA, the current standard assay for ACPA-detection. 
Though important to note, 18% of the CCP negative patients were positive for at least 
one ACPA fine-specificity. Conversely, nearly 14% of the CCP positive patients were 
negative for the four ACPA fine-specificities, and this subset also showed some 
association with HLA-DRB1 SE, clearly indicating that other ACPA targets exist, 
which has also been reported,[25, 30, 31], and should be considered in future studies.  
 
Our peptide-absorption experiments showed that the ACPAs were mainly non-cross-
reactive. Although some degree of cross-reactivity was observed in some sera, the 
majority did not demonstrate cross-reactivity, in line with previous reports,[9, 14]. 
Hence we consider these ACPAs as four distinct fine-specificities, and subsequently 
we base our RA subsets on the presence or absence of anti-CEP-1, anti-Cit-vim, anti-
Cit-fib and anti-Cit-C1 antibodies, rather than CCP status. The fact that the ACPAs 
occur together in some patients, but on their own in others, imply that their production 
may be governed by partly different mechanisms. It is therefore very interesting to 
note the specific relationship between HLA-DRB1 SE and certain ACPA fine-
specificities (in particular CEP-1 and Cit-vim), but not others (mainly Cit-fib).  
 
The estimated risks in some of the analyses should be viewed in the context of small 
sample sizes, with large confidence intervals. Still, our data collectively points to 
clear differences between ACPA fine-specificities, thus confirming and extending 
previous reports,[11-13]. Importantly, the present study answer the previously 
unanswered question,[32], concerning the influence of HLA-DRB1 SE on the 
specificity versus the magnitude of the ACPA response. Notable is also the fact that 
the effects of smoking and PTPN22, in the context of HLA-DRB1 SE, appear to be 
most pronounced in subsets defined by multiple ACPAs where reactivity to CEP-1 is 
present. These data may suggest that smoking is involved in citrullinating and 
exposing some, but not other, autoantigens to the immune system, and that PTPN22 
exerts its effects only when certain MHC class II dependent immune reactions are 
involved. These data will form the basis for future experimental studies, on molecular 
pathways of relevance for disease development in distinct subsets of RA. 
 
In summary, our data highlight the complexity of the gene-environment influence on 
ACPA positive RA. A particularly interesting finding is that HLA-DRB1 SE together 
with PTPN22 and smoking, associate so strongly with the presence of anti-CEP-1 
antibodies on one hand, and anti-Cit-vim antibodies on the other hand, but mainly 
with the simultaneous presence of both ACPAs. Since the ‘shared epitope’ comprise 
several different alleles, and since a dose-effect has been demonstrated for the HLA-
DRB1 SE association,[4, 5, 11], one may speculate that peptides from citrullinated α-
enolase may be preferentially presented by one specific SE allele and subsequently 
trigger the production of anti-CEP-1 antibodies, while peptides from citrullinated 
vimentin are preferentially presented by another SE allele, giving rise to anti-Cit-vim 
antibodies. Hence, in such a scenario, presence of two different SE alleles would 
drive the simultaneous production of two different ACPAs, which may tentatively 
synergize in contributing to the development of RA. Detailed studies of the SE alleles, 
other MHC class II alleles, as well as other genetic polymorphisms and environmental 
exposures, in the context of different ACPA fine-specificities, will increase our 
understanding of the etiology in different subsets of ACPA positive RA. Results from 
such studies may also help to develop future personalised therapies for patients with 
rheumatoid artrhritis, and preventive strategies for individuals at risk of developing 
the disease. 
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FIGURES  
 
 
 
Figure 1 Subsets of RA, defined based on the presence (+) or absence (-) of four 
different ACPA fine-specificities (CEP-1, Cit-vim, Cit-fib and Cit-C1), as detected by 
ELISA. A) 1985 RA cases. B) 730 anti-CCP negative RA cases. In panel A, subsets 
may comprise CCP positive and CCP negative RA cases, with percentages of anti-
CCP positive cases shown in brackets. 
 
	  
 
 
Figure 2 Cross-reactivity between different ACPA fine-specificities. Antibody 
responses to CEP-1, Cit-vim, Cit-fib and Cit-C1 was measured in serum samples from 
10 CCP positive RA patients (RA1 - RA10), after pre-absorption with the different 
peptides. A) anti-CEP-1 IgG levels; B) anti-Cit-vim IgG levels; C) anti-Cit-fib IgG 
levels; D) anti-Cit-C1 IgG levels. Serum samples that were negative for one or several 
ACPA fine-specificities were removed from those specific analyses: RA6 and RA10 
(B); RA9 (C); RA5 and RA9 (D). Log scales of AU/ml values are shown on the Y-
axis. Dotted lines indicate cut-off for positivity (10AU/ml). X-axis indicate pre-
absorbing peptides, or no peptide (buffer alone). Asterisks indicate significant 
differences in relation to ‘no peptide’. *** p < 0.0001; ** p < 0.001; * p < 0.05. 
 
	  	  	  
Figure 3 The combined effect of HLA-DRB1 SE, PTPN22 and smoking, on disease 
risk in different subsets of RA. Odds ratios (OR), with 95% confidence intervals (CI), 
were calculated using unconditional logistic regression analysis, by comparing 
individuals that were positive for the risk factors with individuals that were negative. 
RA subsets were defined based on the presence or absence of one ACPA fine-
specificity, without taking into account which other ACPA fine-specificities may be 
present simultaneously. A) anti-CEP-1; B) anti-Cit-vim; C) anti-Cit-fib; D) anti-Cit-
C1. White bars show subsets negative for the ACPA fine-specificity and negative for 
CCP (-/-); grey bars show subsets negative for the ACPA fine-specificity, but positive 
for CCP (-/+); black bars show subsets positive for the ACPA fine-specificity, but 
where the CCP status was not considered (+/ + or -). 95% CI for the (-/+) and the (+ / 
+ or -) subsets are: 4.58-13.53 versus 19.07-79.97 (A); 5.03-15.68 versus 13.95-47.02 
(B);  7.55-22.10 versus 8.51-28.64 (C); 7.55-24.49 versus 6.07-16.49 (D). The 
asterisk indicate non-overlapping 95% CI. 
 
SUPPLEMENTARY METHODS 
 
ELISAs 
Antibody responses to citrullinated peptides from α-enolase (CEP-1), vimentin (Cit-
vim), fibrinogen (Cit-fib) and collagen type II (Cit-C1), or the arginine-containing 
equivalents, were assayed in sera from 1985 EIRA cases and 150 randomly selected 
EIRA controls, using in-house ELISAs, as previously described,[11, 19]. Briefly, 96-
well plates (MaxiSorp, Nunc) were coated with CEP-1 at 5µg/ml, or Cit-C1 at 
10µg/ml, and incubated at 4°C over night. Alternatively, 96-well plates 
(Streptavidine, Pierce, Thermo Scientific) were washed in PBS, 0.05% Tween, prior 
to coating with biotinylated Cit-vim or Cit-fib peptides, at 1µg/ml, for 1h. Plates were 
washed and blocked with 1% BSA in PBS for 1h at room temperature (only CEP-1 
and Cit-C1 plates), before adding serum samples, diluted 1:100 in RIA buffer (10mM 
Tris, 1% BSA, 350mM NaCl, 1% Triton-X, 0.5% sodium deoxycholate, 0.1% SDS) 
and incubated for 1h at room temperature. A standard curve, with serial dilutions of a 
positive serum pool, for each peptide ELISA, as well as a blank (RIA buffer), a 
positive and a negative control serum, were included on all plates. All samples were 
analysed in duplicates. Plates were subsequently washed and incubated for 1h at room 
temperature, with horse radish peroxidase (HRP)-conjugated goat anti-human IgG 
(Jacksson), diluted 1:10,000 in RIA buffer. After a final wash, TMB substrate 
(Sigma) was added for approximately 15 minutes (1h for Cit-C1), before the reaction 
was stopped by adding 1M H2SO4, and absorbance determined at 450nm. Optical 
density was expressed as arbitrary units (AU/ml), based on the standard curves. The 
cut-off values for positive samples were determined based on the 98th percentile 
among 150 controls, and subsequently converted to 10AU/ml for all ACPA fine-
specificities. 
 
Each ELISA was optimized independently. The CEP-1 and the Cit-C1 peptides, 
which were synthesized to contain cysteins at the N and C terminus (CEP-1) or in a 
triple helical form (Cit-C1), and therefore likely to expose conformational epitopes, 
were coated directly onto MaxiSorp Nunc plates, while the linear peptides Cit-vim 
and Cit-fib were biotinylated and coated onto streptavidine plates, to enhance the 
likelihood of exposing conformational epitopes. 
 
 
 
SUPPLEMENTARY TABLES 
 
 
Supplementary Table 1. Citrullinated peptides 
peptide protein amino acids amino acid sequence 
CEP-1 α-enolase 5-21 C-KIHA-cit-EIFDS-cit-GNPTVE-C 
Cit-vim vimentin 60-75 VYAT-cit-SSAV-cit-L-cit-SSVP-K-biotin 
Cit-fib fibrinogen, β-chain 36-52 biotin-NEEGFFSA-cit-GHRPLDKK 
Cit-C1 collagen type II 359-369 (GPP*)5-GA-cit-GLTG-cit-P*-GDA-(GPP*)2-GKKYG 
      
cit = citrulline     
P* = hydroxyproline     
Supplementary Table 2. Odds ratios for disease risk in different subsets of RA - in subjects exposed 
to different combinations of HLA-DRB1 SE and PTPN22, compared to non-exposed subjects  
CEP-1/Cit-vim/Cit-C1 HLA-DRB1 SE PTPN22 Cases/controls OR* 95% CI 
-/-/- - - 241/477 1.0  Ref. 
-/-/- + - 339/520 1.3  1.1-1.6 
-/-/- - + 91/154 1.2  0.9-1.6 
-/-/- + + 128/119 2.3  1.7-3.1 
+/-/- - - 10/477 1.0  Ref. 
+/-/- + - 59/520 5.5  2.8-10.9 
+/-/- - + 8/154 2.4  0.9-6.2 
+/-/- + + 20/119 8.7  3.9-19.2 
-/+/- - - 21/477 1.0  Ref. 
-/+/- + - 87/520 3.8  2.3-6.3 
-/+/- - + 5/154 0.8  0.3-2.1 
-/+/- + + 39/119 8.4  4.7-14.9 
-/-/+ - - 43/477 1.0  Ref. 
-/-/+ + - 102/520 2.2  1.5-3.2 
-/-/+ - + 25/154 1.9  1.1-3.2 
-/-/+ + + 24/119 2.3  1.4-4.0 
+/+/- - - 8/477 1.0  Ref. 
+/+/- + - 111/520 13.3  6.4-27.6 
+/+/- - + 4/154 1.7  0.5-5.6 
+/+/- + + 51/119 29.2  12.9-61.6 
+/-/+ - - 10/477 1.0  Ref. 
+/-/+ + - 66/520 6.2  3.2-12.3 
+/-/+ - + 6/154 2.0  0.7-5.6 
+/-/+ + + 38/119 17.1  8.2-35.8 
-/+/+ - - 14/477 1.0  Ref. 
-/+/+ + - 65/520 4.3  2.4-7.8 
-/+/+ - + 3/154 0.7  0.2-2.5 
-/+/+ + + 28/119 8.7  4.4-17.3 
+/+/+ - - 12/477 1.0  Ref. 
+/+/+ + - 178/520 14.0  7.7-25.6 
+/+/+ - + 9/154 2.4  1.0-5.7 
+/+/+ + + 96/119 34.8  18.4-65.9 
*:Adjusted for age, gender and residential area   
 
 
  
 
 
SUPPLEMENTARY FIGURES 
 
 
 
 
 
Supplementary figure 1 Anti-CCP antibody levels in different anti-CCP positive 
subsets of RA, defined based on the number of ACPA fine-specificities present (1, 2, 
3 or 4). Box plot whiskers show anti-CCP levels (AU/ml) within the 10th-90th 
percentile. The median value for each subset is indicated as a line within the boxes. 
*** p < 0.0001.  
Supplementary Table 3. Interaction (calculated as the attributable proportion (AP) due to 
interaction) between HLA-DRB1 SE and smoking, and between HLA-DRB1 SE and 
PTPN22, in different subsets of RA 
RA subset HLA-DRB1 SE - smoking HLA-DRB1 SE - PTPN22 
CEP-1/Cit-Vim AP 95% CI AP 95% CI 
-/- 0.11 -0.17-0.39 0.24 -0.01-0.50 
+/- 0.33 0.09-0.58 0.44 0.21-0.67 
-/+ 0.21 -0.08-0.51 0.56 0.38-0.74 
+/+ 0.64 0.53-0.76 0.53 0.40-0.67 
 
 
 
 
 
 
 
 
 
Supplementary figure 2 Anti-CCP antibody levels in two different anti-CCP positive 
subsets of RA, each defined based on the sole presence of two ACPA fine-
specificities: CEP-1 and Cit-vim (grey bar); Cit-fib and anti-Cit-C1 (white bar). Box 
plot whiskers show anti-CCP levels (AU/ml) within the 10th-90th percentile. The 
median value for each subset is indicated as a line within the boxes. ** p = 0.0025.  
 
 
